Summit Therapeutics total depreciation and amortization - cash flow for the twelve months ending March 31, 2025 was $0.000B, a 56.9% decline year-over-year.
Summit Therapeutics annual total depreciation and amortization - cash flow for 2024 was $0B, a 55.05% decline from 2023.
Summit Therapeutics annual total depreciation and amortization - cash flow for 2023 was $0B, a 92.12% decline from 2022.
Summit Therapeutics annual total depreciation and amortization - cash flow for 2022 was $0.003B, a 2.4% increase from 2021.
Summit Therapeutics Total Depreciation and Amortization - Cash Flow 2015-2025 | SMMT